1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials

Clinical Trials In China: As US Lawmakers Consider Crackdown, Here Are The Implications

 
• By Sarah Karlin-Smith

If the US Congress continues to target trials at Chinese military hospitals, the impact could be relatively small, while a broader focus could upend multinational development programs. 

map of China
Some US lawmakers want to crack down on clinical trials conducted in China. • Source: Shutterstock

A bipartisan group of US lawmakers’ concerns about clinical trials conducted at Chinese military hospitals likely would have a minimal impact on late-stage drug development if the attention translated to legislation cracking down on the US Food and Drug Administration’s ability to review applications with that data.

Key Takeaways

  • Only about 1% to 4% of the sites currently qualified and conducting Phase III research in China are military hospitals.

  • Chinese sites, including military and nonmilitary, make up a relatively small share of those conducting multinational late-stage research worldwide

Lawmakers recently raised concerns about US pharma company collaborations with the hospitals

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Unlocking Opportunities: How To Engage With The EMA On Animal Testing Alternatives

 
• By Neena Brizmohun

The European Medicines Agency, like its counterpart in the US, is increasingly focusing on the use of alternatives to animal testing.

EU Pharma Reform: Exclusivity Vouchers Alone Are Insufficient Incentive For Antimicrobials, Industry Says

 
• By Eliza Slawther

European pharma trade associations EFPIA and EUCOPE outline their respective views on how the EU’s pharma legislation overhaul should tackle antimicrobial resistance, and why transferable exclusivity vouchers alone will not suffice as incentives.

What The EMA Can Teach HTA Bodies About Joint Clinical Assessments

 
• By Francesca Bruce

EU-level joint clinical assessments conducted under the Health Technology Assessment Regulation need to be more flexible when it comes to evidence requirements, according to experts speaking at a gene and cell therapy conference.